meRfi®-GM
Sialyl-Tn (STn) / Neu5Acα2-6GalNAc-O-Ser/Thr
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
The emergence of STn is thought to be partly caused by aberrant expression of ST6GalNAc I sialyltransferase (ST6GALNAC1)
Tumour associated STn is associated with poor prognosis and re- sistance to chemotherapy in breast carcinomas, inhibition of DC maturation, DC apoptosis and inhibition of NK activity
Beatson et al. 2015
STn is expressed by more than 80% of human carcinomas
Julien et al., 2012
Anti-cancer vaccine, Theratope, has been designed towards the STn epitope
Julien et al., 2012
STn weakly expressed by fetal and normal adult tissues
Julien et al., 2012
Many anti-STn antibodies have been developed since the mid 80s
…
References (Sources)
- Early Murine T-lymphocyte Activation Is Accompanied by a Switch from N-Glycolyl- to N-Acetyl-neuraminic Acid & Generation of Ligands for Siglec-E
- Expression of Tn, sialosyl-Tn, and T antigens in human colon cancer
- RNAi-mediated gene silencing of ST6GalNAc I suppresses the metastatic potential in gastric cancer cells
- Sialosyl Tn antigen expression is associated with the prognosis of patients with advanced gastric cancer
- Siatyltransferase mRNA abundances in B cells are strictly controlled, correlated with cognate lectin binding, and differentially responsive to immune signaling in vivo
- Tumor-associate CD75s and iso-CD75s-gangliosides are potential targets for adjuvant therapy in pancreatic cancer
- Tumor-Associated antigens: Tn antigen, sTn antigen, and T antigen